Abstract
Etiology
Unknown.
Epidemiology
Only one case to date, a 10-year-old male patient (Nadal et al., 2012) .
Clinics
Lymphadenopathies, enlarged spleen and liver. Central nervous system involvement.
Cytology
High WBC with blast cells (44%), myelemia, eosinophilia and basophilia. Bone marrow aspiration showed 60% of undifferentiated blast cells with persistence of the granulocytic lineage.
Treatment
The patient was treated according to the European protocol ESPHALL (imatinib, asparaginase, vincristine, vindesine, daunorubicin, aracytine, VP16 , ifosfamide, and methotrexate, followed by an allograft).
Evolution
After induction, minimal residual disease (MRD) detection by CMF and by molecular analysis was negative, whereas RT-PCR for BCR-ABL1 transcript was still positive. Chromosomal examination showed the presence of one metaphase out of 30 with only the t(9;22)(q34;q11), suggesting that the t(9;14) translocation was a secondary chromosomal abnormality. Thus, the chemotherapy had eradicated the lymphoblast cells but a CML clone persisted, further supporting the diagnosis of CML in BC. By 7 months after diagnosis, the patient underwent allogenic stem cell transplantation from his HLAmatched sister. At 2 years post-transplantation, the patient was alive and well. BCR-ABL1 transcript was undetectable (<0.001%).
Cytogenetics

Additional anomalies
The t(9;14)(q33;q32) translocation appears as a secondary abnormality occurring at acutisation of a CML with the usual t(9;22)(q34;q11) with a breakpoint in the mBCR region. The latest is usually observed in BCR-ABL1+ de novo acute lymphoblastic leukemia but is rare in CML. i(7)(q10), present in 2 out of the 20 metaphases analyzed using conventional karyotype, and in 3/100 metaphases using FISH (7q22/7q36 DualColor probe, Kreatech Diagnostics). 
439
A. Conventional karyotype: partial R and G-banded karyotype. The derivative chromosomes of translocations t(9;14)(q33;q32) and t(9;22)(q34;q11) are denoted by solid and dotted arrows, respectively. B. FISH: representative metaphase hybridized with dual color break-apart IGH probe (Abbott, Rungis, France). A fusion signal is seen on normal chromosome 14 (large arrows), a red signal on derivative chromosome 14 (small solid arrows) and a green signal on derivative chromosome 9 (small dotted arrows). C. FISH: representative metaphase hybridized with a BCR/ABL ES probe (Abbott). A green signal is seen on a normal chromosome 22 (large arrows), and two fusion signals on derivative chromosomes 9 and 22 (small dotted arrows), confirming the BCR-ABL1 rearrangement with a breakpoint in the mBCR region. A red signal is observed on derivative chromosome 14 (small solid arrows), indicating that the breakpoint of t(9;14) was centromeric to the ABL1 gene in chromosome 9.
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Genes involved and proteins
LHX2
Location 9q33 Note LIM homeobox gene LHX2 is a member of the LIM homeobox family of transcription factors characterized by a DNA binding homeodomain and a cystein-rich LIM-domain. LHX2, initially identified as an early marker in B-lymphocyte differentiation (Xu et al., 1993) , is involved in the neurogenesis, hair follicle, and hematopoietic development (Porter et al., 1997) .
IGH
Location 14q32
Result of the chromosomal anomaly
Hybrid gene
Note
The translocation links sequence located 148 kb centromeric of LHX2 on chromosome 9 to JH6 segment on chromosome 14.
Fusion protein
Note
No fusion protein. Oncogenesis LHX2 juxtaposition with the IGH locus results in strong over-expression of LHX2, which may have contributed to the rapid progression in the blastic phase. It has been shown that over-expression of LHX2 in murine hematopoietic precursors leads to the development of chronic myeloproliferative disorders (Richter et al., 2003) . Thus, transcriptional deregulation of LHX2 plays a recurrent role in leukemogenesis.
